FindTrial
Sign In

Dose-Dense Therapy in Aggressive Lymphoma

Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT00517894
Enrollment
Unknown
Registered
2007-08-17
Start date
Unknown
Completion date
Unknown
Last updated
2007-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Keywords

lymphoma, aggressive, chemotherapy, dose-dense

Brief summary

To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.

Detailed description

Patients are randomized to receive dose-dense CEOP/IMVP-Dexa chemotherapy or standard 3-weekly CHOP.

Interventions

DRUGCEOP/IMVP-Dexa chemotherapy

Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28

Sponsors

Arbeitsgemeinschaft medikamentoese Tumortherapie
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years

Inclusion criteria

* 18 and 70 years of age * Centrally reviewed, histologically proven diffuse large B-cell, anaplastic large-cell, or peripheral T-cell unspecified * Measurable disease * All stages

Exclusion criteria

* Lymphoblastic or Burkitt histology * CNS-disease * HIV-positive * pregnant or lactating women * Pretreatment * Other malignancy * Concomitant diseases that forbid chemotherapy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026